Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. [electronic resource]
Producer: 20160404Description: 875-84 p. digitalISSN:- 1744-8328
- Adenocarcinoma -- drug therapy
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Disease-Free Survival
- Docetaxel
- Humans
- Indoles -- administration & dosage
- Lung Neoplasms -- drug therapy
- Molecular Targeted Therapy
- Prognosis
- Survival Rate
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.